Oculogica Receives FDA Marketing Authorization for EyeBOX® Device, the First Non-Invasive, Baseline-Free Test for Concussion

FDA Grants Marketing Authorization for Use in Children 5 and Older and Adults up to 67 Years of Age. January 3, 2019 — NEW YORK– Oculogica, Inc., a pioneer in algorithm-based neuro-diagnostics, announced that the U.S. Food and Drug Administration (FDA) granted their De Novo request for the commercialization of the EyeBOX® device, the first non-invasive, …

Oculogica Receives FDA Marketing Authorization for EyeBOX® Device, the First Non-Invasive, Baseline-Free Test for Concussion Read More »